340B Transparency Act
Latest Action
Placed on the Union Calendar, Calendar No. 628.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The 340B Transparency Act (H.R. 3290) is a health policy bill introduced in the 118th Congress aimed at increasing transparency in the 340B Drug Pricing Program. The bill's text and official summary are not provided, but it is intended to address issues related to the administration and oversight of the 340B program, which allows certain healthcare providers to purchase outpatient drugs at reduced prices. The bill was placed on the Union Calendar but ultimately failed or expired without becoming law.
H.R. 3290 sought to enhance transparency in the 340B Drug Pricing Program but did not advance to enactment during the 118th Congress.
- The bill is focused on the health policy area, specifically the 340B Drug Pricing Program.
- It was introduced in the House of Representatives during the 118th Congress.
- The latest procedural action was placement on the Union Calendar, indicating it was scheduled for floor consideration but did not pass.
['Healthcare providers participating in the 340B program', 'Patients who receive medications through 340B-covered entities', 'Government agencies responsible for oversight of drug pricing programs']
['Lack of available full bill text limits detailed analysis of implementation and enforcement mechanisms.', 'Potential administrative costs associated with increased transparency requirements.', 'Unclear oversight provisions and authority due to missing detailed legislative language.']
The bill was introduced in the House during the 118th Congress and placed on the Union Calendar, which is a step toward floor consideration. However, it did not progress further and is recorded as failed or expired. The 340B program has been subject to ongoing legislative interest due to its role in drug pricing and healthcare provider support.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, increased transparency could lead to changes in how 340B program participants manage drug pricing and compliance.', 'Potential shifts in drug pricing negotiations and healthcare provider reimbursement strategies.', 'Enhanced oversight might affect pharmaceutical manufacturers and supply chains indirectly.']
Due to the absence of the full bill text and official summary, transparency about the bill's specific provisions and mechanisms is limited. This restricts the ability to fully evaluate oversight, enforcement, and cost implications. Monitoring future legislative efforts on 340B transparency should prioritize availability of complete legislative documents for thorough analysis.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.